SUBCUTANEOUS IMMUNOGLOBULIN (SCIG) AUTHORISATION REQUEST FORM FOR EMERGENCY AUTHORISATIONS DURING BLOODSTAR SYSTEM DOWNTIME

NEUROLOGICAL INDICATIONS

IMPORTANT! This is only to be used for emergency initial authorisation requests during BloodSTAR system downtime. This form is for single doses only and must not be used to request maintenance therapy or for routine requests. The details of this authorisation request should be entered into BloodSTAR within 7 working days of the request. If the details are not entered into BloodSTAR within this timeframe, funding of product under the National Blood Arrangements cannot be guaranteed.

About this form: This form is used to request patient specific authorisation from the Australian Red Cross Lifeblood (Lifeblood) for access to SCIg products, assessed against Version 3 of the *Criteria for the Clinical Use of Immunoglobulin in Australia* (the Criteria). All fields must be completed, incomplete forms will delay processing. Completed forms are to be faxed to the relevant contact at the bottom of this form.

Tip: To move to the next field, click TAB on your keyboard.

State/Territory: **Requesting Medical Officer Name:** **Position:**

Pager/Mobile: **Phone:** **Fax:** **Date:**

PATIENT DETAILS (or affix hospital label)

Surname:

Given names:

DOB (DD/MM/YYYY):

Gender: ☐ Female ☐ Male

UR:

Hospital:

SCIg Program Hospital:

Weight: kg Height: cm

PREVIOUS IMMUNOGLOBULIN TREATMENT:

☐ Intravenous Immunoglobulin (IVIg) ☐ CSL SCIg Trial

☐ Other SCIg ☐ Normal Human Immunoglobulin (NHIg) ☐ Unknown

Please provide details below (including date, product and response, if known):

Treating facility (where clinically reviewed):

Administering facility (where Ig given):

Dispensing facility (where Ig dispensed from):

PLEASE INDICATE PATIENT DIAGNOSIS. CONSULTANT'S LETTER MAY BE ATTACHED TO DEMONSTRATE THAT ALL QUALIFYING CRITERIA HAVE BEEN MET.

Chronic inflammatory demyelinating polyneuropathy (CIDP)

☐ Chronic inflammatory demyelinating polyneuropathy (CIDP) ☐ IgA paraproteinaemic demyelinating neuropathy

☐ IgG paraproteinaemic demyelinating neuropathy

Indication

☐ Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) for patients in whom walking is compromised or there is significant disability

☐ Relapse of chronic inflammatory demyelinating polyneuropathy (CIDP) patients within six months of commencement of trial off Ig therapy

Qualifying criteria

☐ Adult or child 10 years or older

Current ONLS score Points

Date of assessment

Comments

What is the MRC sum score Points

Date of assessment

Please describe the level of disability and compromise to walking or previous response to Ig therapy and the change in disability/impairment since stopping Ig treatment if patient has relapsed:

☐ In children less than 10 years

6MWT result Date of assessment

Current MRS score Date of assessment

Please describe the level of disability and compromise to walking or previous response to Ig therapy and the change in disability/impairment since stopping Ig treatment if patient has relapsed:

ONLY A SINGLE DOSE CAN BE AUTHORISED USING THIS EMERGENCY OFFLINE FORM

DOSE REQUIRED: g Total dose per month:

Please indicate your preferred product: ☐ Hizentra AU ☐ Hizentra ☐ Cuvitru ☐ Xembify

OFFICE USE ONLY (TO BE COMPLETED BY LIFEBLOOD AUTHORISER)

Delegate: Designation (MO/TN/Other):

Qualifying Criteria: ☐ Met ☐ Not met Request approved: ☐ Yes ☐ No

Product: Dose: g

SUBCUTANEOUS IMMUNOGLOBULIN (SCIG) AUTHORISATION REQUEST FORM FOR EMERGENCY AUTHORISATIONS DURING BLOODSTAR SYSTEM DOWNTIME

NEUROLOGICAL INDICATIONS

PATIENT DETAILS

Surname: Given names:

DOB (DD/MM/YYYY): Hospital:

REQUESTING MEDICAL OFFICER

Name: Position:

Pager/Mobile: Phone: Fax: Date:

TREATING MEDICAL SPECIALIST Specialty:

Name: Phone: Mobile:

IMPORTANT: The contact details above will be used for any relevant urgent correspondence.

Prescriber acknowledgement and confirmation (to be completed by the Treating Medical Specialist or appropriate delegate following discussion with their patient)

I acknowledge the governance and management arrangements for the appropriate supply and use of immunoglobulin products, funded under the national blood arrangements, and the provision of information required to support authorisation. To the best of my knowledge, the information provided in this form and attachments is true and correct. I have provided and/or explained to my patient (or parent/carer/guardian) the Privacy Statement and Notice (Notice) and Patient Information Brochure and they have had the opportunity to ask questions. I believe that they are aware of and understand:

- the risks and benefits of treatment with immunoglobulin products and alternative treatments (where these exist),
- the national access conditions and governing requirements for the appropriate supply and use of immunoglobulin products under the national blood arrangements, including that immunoglobulin products may need to change from time to time
- (for patients requiring ongoing treatment only) the nature of ongoing monitoring and review and that access to product will cease if response to treatment does not demonstrate clinical benefit.

I confirm that my patient (or parent/carer/guardian) has provided express consent (explicit verbal or written consent) to:

- the collection and recording of personal information (including sensitive health information) in secure databases, held by the Australian Red Cross Lifeblood (Lifeblood) and the National Blood Authority (NBA),
- the use of this information by clinicians to submit a request for, and for the assessment of, initial or ongoing authorisation for access to publicly funded immunoglobulin products, against the criteria determined by clinical experts and approved by Australian governments for this purpose,
- the use of limited identifying details (for example, name, date of birth, sex and hospital identifiers) within search functions of the above mentioned databases to ensure that patients are correctly identified,
- the disclosure to and use of this information by clinicians in Australian treatment facilities that they attend for health care, in order to deliver health services according to the purposes set out in the Notice and
- the disclosure and use of this information in a manner which will not readily identify them, (such as through the removal of directly identifying personal information, or use of summary level grouped data) for the secondary purposes of: identifying priorities for research, prescriber education and training; performance evaluation and improvement of the supply, authorisation and use of immunoglobulin products; further developing the criteria upon which government policy is based; supply planning so the NBA can make sure enough Ig products are available to meet patients' needs; and enabling reporting on the program for supply, authorisation and use of publicly funded immunoglobulin products.

My patient understands that any additional use of information held by Lifeblood and the NBA will only be undertaken in accordance with the requirements of the Privacy Act 1988 (Cth) and any relevant state/territory laws, and that the information may be made available for medical or public health research only with approval of a properly constituted human research ethics committee (HREC). I also confirm:

- my patient is suitable for self-administered treatment within a participating hospital based SCIg program (as specified on page 1 of this form), and
- the approved access conditions and governing requirements will be complied with through the hospital based SCIg program.

Signature: **Date:**

Name: **Position:**

The National Blood Authority contracts Australian Red Cross Lifeblood to perform the roles of Authoriser and Distributor of immunoglobulin products supplied and funded under the national blood arrangements.

AUTHORISATION REQUESTS MUST BE PRECEDED BY, OR IMMEDIATELY FOLLOWED UP WITH, A TELEPHONE CALL TO LIFEBLOOD.
PLEASE COMPLETE, PRINT, SIGN AND FAX TO THE RELEVANT FAX NUMBER PROVIDED BELOW.

STATE	FAX TO:	FOR URGENT ENQUIRIES
ACT	02 9234 2050	1300 478 348 (After Hours: 1300 478 348)
NSW	02 9234 2050	1300 478 348 (After Hours: 1300 478 348)
NT	08 8927 5461	08 8928 5116 (After Hours: 1300 478 348)
QLD	07 3838 9421 (8:30am-4:30pm) or 07 3838 9400	07 3838 9223 (After Hours: 07 3838 9010)
SA	08 8223 5833 (After Hours: 08 8225 8199)	08 8112 1341 (After Hours: 1300 136 013)
TAS	03 9694 0245	03 9694 0200 (After Hours: 03 9694 0200)
VIC	03 9694 0245	03 9694 0200 (After Hours: 03 9694 0200)
WA	08 9221 1215	08 9421 2377 (After Hours: 08 9325 3030)